Following repeated intravenous gadodiamide in healthy male rats, brain gadolinium remained measurable through 50 weeks. Light microscopy and ultrastructural examination found no treatment-related brain morphology changes under the reported conditions. Functional neurological safety was not established. [2]
After a single 0.6 mmol/kg intravenous gadodiamide dose in healthy male rats, total gadolinium declined in cerebellum, kidney and femur but remained measurable at 20 weeks. These measurements do not distinguish intact gadodiamide from other gadolinium-containing species, and the kinetic study lacked untreated controls. [2]
Brain retention and morphology after repeated gadodiamide
Animal study · Healthy male Sprague Dawley rats, 6 weeks old at purchase; n=6 per group/time point for repeat-dose brain ICP-MS and histopathology; TEM n=3 per group. [2]
Measurable brain gadolinium persisted through 50 weeks after repeated dosing. No treatment-related brain morphology changes were reported by light microscopy or TEM. Morphological observations do not establish absence of functional effects.
Conditions shared by the study groups
- Route
- Intravenous, lateral tail vein
- Frequency
- 4 times weekly
- Treatment course
- 5 weeks; follow-up through 50 weeks
- Repeated gadodiamide
- Model: Healthy male Sprague Dawley rats, 6 weeks old at purchase; n=6 per group/time point for repeat-dose brain ICP-MS and histopathology; TEM n=3 per group.
Methods and source locations
Compound reported in the paper: Gadodiamide; Compound label in the paper: Gadodiamide supplied by GE Healthcare; brand and excipient composition not specified in the read methods
Healthy male rat retention and morphological observations under a high cumulative exposure; no human safety inference.
Materials and methods: Animals; Histopathology; Transmission electron microscopy ultrastructural analysis; ICP-MS. Results: Trace levels persisted; Table 1; Figure 1 and caption; Discussion limitations.
Whole-brain gadolinium after the repeat-dose course: ICP-MS on one hemisphere; total elemental Gd, without chemical speciation. — Table 1, including SD column and caption; ICP-MS methods.
Treatment-related brain morphological findings: Independent toxicologic histopathologist assessed light microscopy at three brain levels; TEM of deep cerebellar nuclei, treatment-blinded. Incidental findings occurred in controls and treated groups. — Histopathology and TEM ultrastructural methods; Results first subsection; Figure 1 and caption.
Repeated gadodiamide · Materials and methods: Animals; Histopathology; Transmission electron microscopy ultrastructural analysis; ICP-MS. Results: Trace levels persisted; Table 1; Figure 1 and caption; Discussion limitations.
Tissue gadolinium after a single gadodiamide injection
Animal study · Healthy male Sprague Dawley rats; n=3 per sampling time point; separate single-dose cohorts studied at QPS. [2]
Total gadolinium in cerebellum, kidney and femur declined between 1 hour and 20 weeks but remained measurable. Tissue kinetics measure total Gd and cannot determine how much remains as intact gadodiamide. The design had no untreated kinetic-control group.
Conditions shared by the study groups
- Route
- Intravenous, lateral tail vein
- Frequency
- Once
- Treatment course
- Follow-up through 20 weeks
- Single gadodiamide dose
- Model: Healthy male Sprague Dawley rats; n=3 per sampling time point; separate single-dose cohorts studied at QPS.
- Reported limits: Exact formulation not specified; no untreated kinetics controls.
Methods and source locations
Compound reported in the paper: Gadodiamide; Compound label in the paper: GE-supported single-dose gadodiamide study; exact formulation unspecified
Tissue total-Gd kinetics in healthy male rats at the stated dose; no human dose conversion or functional-safety conclusion.
Materials and methods: Animals; ICP-MS; Statistical analysis. Results: Gadolinium detected after single administration; Table 2 tissue rows and Table 3; Figures 4–5 and captions; Discussion limitations.
Whole-cerebellum total gadolinium: ICP-MS after transcardial perfusion; Figure 5a viewed; exact numbers taken from Table 2. — Table 2, Whole cerebellum row; Figure 5a and caption.
Left-kidney total gadolinium: ICP-MS; Figure 5b viewed; exact numbers taken from Table 2. — Table 2, Left kidney row; Figure 5b and caption.
Femur total gadolinium: ICP-MS; Figure 4g viewed; exact numbers taken from Table 2. — Table 2, Femur bones row; Figure 4g and caption.
Single gadodiamide dose · Materials and methods: Animals; ICP-MS; Statistical analysis. Results: Gadolinium detected after single administration; Table 2 tissue rows and Table 3; Figures 4–5 and captions; Discussion limitations.